Developer docs
API playgroundTry for free, no card

Search company profiles

STELLA PHARMA

Full company profile

uuid00045gs

Namestring
STELLA PHARMA
Legal namestring
ステラファーマ株式会社 (STELLA PHARMA CORPORATION)
Company typeenum
Public
Founded yearint
2007
Descriptiontext

STELLA PHARMA (TSE Growth: 4888) is a Japan-based, publicly traded specialty pharmaceutical company founded in 2007 as a vehicle to commercialize Boron Neutron Capture Therapy (BNCT) drugs. The company originated inside Stella Chemifa, the only domestic holder of high-purity boron-10 isotope enrichment technology, and has built its franchise on Steboronine® (borofalan (10B), development code SPM-011) — the world's first BNCT boron pharmaceutical to receive marketing approval (Japan, March 2020) and national health insurance reimbursement (effective May 2020) for unresectable locally advanced or locally recurrent head and neck cancer. The drug pairs an enriched boron-10 compound with external neutron irradiation to selectively destroy cancer cells while sparing surrounding tissue, typically in a single ~40-minute session. The company is actively pursuing indication expansion (recent MAA submissions in March 2026 for angiosarcoma and recurrent high-grade meningioma) and assessing thoracic solid tumors, supported by Phase II data showing median PFS of 14.4 vs 1.4 months in recurrent meningioma and 50% ORR in angiosarcoma.

The business model is a single-asset specialty pharma selling a high-value, reimbursement-covered boron drug directly to BNCT-capable medical institutions, with revenue tightly coupled to the installed base of accelerator-based neutron irradiation systems. Go-to-market is sales-led and education-driven: Stella Pharma co-hosts symposia at major Japanese oncology and head-and-neck surgical societies with Sumitomo Heavy Industries (manufacturer of the NeuCure™ BNCT treatment system), runs physician webinars (120+ participants), and supports patient education. Distribution is direct to a small number of treatment centers in Japan (Osaka Medical and Pharmaceutical University Kansai BNCT Medical Center, Minami Tohoku BNCT Research Center, National Cancer Center) and is being extended internationally through the TAE Life Sciences partnership for the USA/Europe and the Pengbo (Hainan) BNCT Hospital in China (opened February 2026, first overseas BNCT site using Japanese-approved pharmaceutical and equipment). The company remains in early commercialization with revenue not publicly disclosed, headcount of 11–50, and faces a material supply-chain disruption following the September 2025 bankruptcy filing of its contract manufacturer.

Short descriptiontext

STELLA PHARMA (TSE Growth: 4888) is a Japan-based specialty pharmaceutical company developing Steboronine®, the world's first approved Boron Neutron Capture Therapy (BNCT) boron drug, sold to BNCT treatment centers and hospitals for head and neck cancer and pipeline oncology indications in Japan, China, the US, and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOsaka, Japan
HQ citystring
Osaka
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
BNCT pharmaceuticals, radiation oncology drugs, boron drug development, neutron capture therapy, cancer therapy products
Industry3 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAE
Radiopharmacy Compounding & Dispensing (Hospital/Commercial)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAKAFAC
Radiation Oncology
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Radiation Therapy Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Sales - Steboronine®
TypeOne Time License
Description

Sale of BNCT boron pharmaceutical drugs (Steboronine®) for treatment of unresectable locally advanced or locally recurrent head and neck cancer. The drug is used in combination with neutron irradiation systems at BNCT treatment facilities.

stella-pharma.co.jp
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Steboronine (ステボロニン)
Description

BNCT (Boron Neutron Capture Therapy) boron pharmaceutical product; the world's first approved BNCT drug. Approved in Japan in March 2020 for unresectable locally advanced or locally recurrent head and neck cancer.

stella-pharma.co.jp
Core offering1 text field

STELLA PHARMA develops and commercializes pharmaceutical drugs for Boron Neutron Capture Therapy (BNCT), a radiation therapy that combines a boron-containing drug with neutron irradiation to selectively destroy cancer cells. Its core product, Steboronine® (borofalan (10B), SPM-011), is the world's first approved BNCT boron pharmaceutical, approved in Japan in March 2020 for unresectable locally advanced or locally recurrent head and neck cancer. The company supplies the drug to medical institutions equipped with accelerator-based neutron irradiation systems (such as Sumitomo Heavy Industries' NeuCure™), enabling single-session targeted cancer treatment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Head and neck cancer treatment outcomes: Tumor shrinkage confirmed in all reported BNCT treatment cases at insurance-covered facilities
+2 more records
Product overview1 text field

STELLA PHARMA is a pharmaceutical company specializing in BNCT (Boron Neutron Capture Therapy) drugs. The company's core product is Steboronine® (development code SPM-011), the world's first approved BNCT pharmaceutical containing enriched boron-10. This drug is used in combination with accelerator-based neutron irradiation systems (such as Sumitomo Heavy Industries' NeuCure™) to selectively destroy cancer cells. BNCT represents a new category of radiation therapy where a single treatment session can complete treatment, targeting cancer cells while preserving surrounding healthy tissue. The company is pursuing indication expansions for recurrent meningioma, angiosarcoma, recurrent high-grade meningioma, and solid tumors.

Product and service2 records
1Steboronine® (ステボロニン®) / Borofalan (10B) / SPM-011
CategoryBNCT Pharmaceutical
Description

World's first approved BNCT (Boron Neutron Capture Therapy) pharmaceutical drug containing enriched boron-10 (borofalan), used in combination with neutron irradiation for targeted cancer treatment. Approved for unresectable locally advanced or locally recurrent head and neck cancer. Sold to BNCT-equipped medical institutions.

2BNCT (Boron Neutron Capture Therapy) Treatment System Supply
CategoryCancer Treatment System
Description

Integrated BNCT treatment offering that pairs STELLA PHARMA's Steboronine® drug with accelerator-based neutron irradiation systems (e.g., Sumitomo Heavy Industries' NeuCure™). When boron-10 absorbs thermal neutrons, it produces alpha particles and lithium nuclei that selectively destroy cancer cells while minimizing damage to surrounding healthy tissue. Treatment is typically completed in a single session of approximately 40 minutes.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Pengbo (Hainan) BNCT Hospital / 鵬博(海南)BNCTセンター
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-02-07
Description

First overseas BNCT facility to use Japanese-approved pharmaceuticals and medical equipment. Located in Hainan Boao Lecheng International Medical Tourism Pilot Zone, China. Stella Pharma supplies BNCT drugs; facility officially opened February 2026 with Sumitomo Heavy Industries BNCT system installed.

stella-pharma.co.jp
2Sumitomo Heavy Industries Co., Ltd. (住友重機械工業株式会社)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-13
Description

Joint development and commercialization partnership for BNCT treatment systems in Japan and globally. Sumitomo Heavy Industries develops and manufactures accelerator-based neutron irradiation systems (NeuCure™) while Stella Pharma supplies the boron pharmaceutical (Steboronine®). The companies jointly conduct clinical trials and promotional activities including academic conference seminars.

stella-pharma.co.jp
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-11-13
Description

Strategic partnership for development and commercialization of BPA (boronophenylalanine) for BNCT cancer therapy in USA and Europe. Signed at TLS headquarters in California, the partnership aims to expand BNCT market in Western regions. CEO Rob from TLS and President Ehara from Stella Pharma participated in signing ceremony.

4Stella Chemifa Co., Ltd. (ステラケミファ株式会社)
Strategic tierCoreTypeTechnology or Integration
Description

Parent company and exclusive domestic holder of boron isotope enrichment technology in Japan. Provides 10B isotope enrichment capabilities (99%+ concentration) essential for BNCT pharmaceutical production.

stella-pharma.co.jp
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partnership for BNCT research. Professor Kirihata from Osaka Metropolitan University BNCT Research Center collaborated on research and development of boron pharmaceuticals.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partnership for BNCT research and development. Kyoto University Research Reactor was used for early BNCT clinical research. Company leveraged Kyoto University research as foundation for drug development.

7Osaka Medical and Pharmaceutical University Kansai BNCT Medical Center (大阪医科薬科大学関西BNCT共同医療センター)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Primary BNCT treatment facility in Japan; key site for clinical trials and treatment delivery. Professor Aihara from the center serves as key opinion leader and frequently presents BNCT clinical data at conferences.

stella-pharma.co.jp
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading cancer treatment hospital conducting BNCT treatments and clinical trials. Dr. Igaki from the hospital participates in BNCT education and awareness activities, including TV media appearances.

9Japan Agency for Medical Research and Development (AMED) / 国立研究開発法人日本医療研究開発機構
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Government research funding agency providing support for BNCT drug development. Company received A-STEP and ACT-M program support for clinical development and novel formulation research.

stella-pharma.co.jp
10Sagamihara General Hospital (湘南鎌倉総合病院)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration on enhanced proton beam therapy using boron compounds. Company provides reagents for research study on cell killing effect enhancement published in Scientific Reports.

stella-pharma.co.jp
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint clinical trial partnership for BNCT treatment of angiosarcoma. CICS provides neutron irradiation system (CICS-1) while Stella Pharma supplies boron drug (SPM-011) for Phase II clinical trial.

12China Biotech Services Holdings Limited / 中国生物科技服務控股有限公司 (Hong Kong Stock Exchange: 8037)
Strategic tierFlagshipTypeGTM or Marketing Partner
Description

Chinese partner company for Hainan Island BNCT center operations. Publicly listed company managing Pengbo BNCT hospital in Boao Lecheng zone. Awarded recognition for BNCT technology at 6th China International Consumer Goods Expo.

stella-pharma.co.jp
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Manufacturer of the NeuCure™ accelerator-based BNCT system used in conjunction with Steboronine®; a strategic co-development partner but also an adjacent competitor/ecosystem gatekeeper in the BNCT value chain.

TypeDirect peer
Description

US-based BNCT company developing accelerator systems and BPA-based boron drugs; signed a strategic partnership with Stella Pharma in Nov 2024 to commercialize BPA in USA/Europe — directly comparable BNCT drug-and-device player.

TypeBroad incumbent
Description

Leader in therapeutic radiopharmaceuticals (e.g., Pluvicto for prostate cancer, Lutathera) — overlaps with Stella Pharma's targeted radionuclide therapy positioning in oncology.

TypeBroad incumbent
Description

Major radiopharmaceutical player with Xofigo (Ra-223) for bone metastases — comparable therapeutic radiopharmaceutical business with established oncology distribution.

TypeDirect peer
Description

US-listed radiopharmaceutical company specializing in diagnostic and therapeutic radioisotopes — comparable business model in radiopharma drug development and commercialization.

TypeDirect peer
Description

Radiopharmaceutical company developing diagnostic and therapeutic agents (e.g., Illuccix, TLX591) — directly comparable in targeted radioisotope drug development pipeline.

TypeDirect peer
Description

Manufacturer of medical radioisotopes (including Lu-177) and developer of targeted radiopharmaceuticals — comparable in isotope-based oncology therapeutics.

TypeOthers
Description

Operates one of the largest radiopharmacy networks (Nuclear & Precision Health Solutions) — relevant ecosystem peer for distribution/compounding of short-lived radioisotope drugs.

TypeOthers
Description

Radiopharmacy network producing PET tracers and distributing radiopharmaceuticals — relevant comparator for commercial-scale isotope drug distribution logistics.

10Ion Beam Applications (IBA)
TypeRegional player
Description

Belgian proton therapy equipment manufacturer; adjacent player in particle-beam radiation therapy ecosystem relevant to BNCT's positioning vs proton therapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

STELLA PHARMA

Radiation Therapy Pharmaceuticalsstella-pharma.co.jp

STELLA PHARMA (TSE Growth: 4888) is a Japan-based specialty pharmaceutical company developing Steboronine®, the world's first approved Boron Neutron Capture Therapy (BNCT) boron drug, sold to BNCT treatment centers and hospitals for head and neck cancer and pipeline oncology indications in Japan, China, the US, and Europe.

What STELLA PHARMA does

STELLA PHARMA (TSE Growth: 4888) is a Japan-based, publicly traded specialty pharmaceutical company founded in 2007 as a vehicle to commercialize Boron Neutron Capture Therapy (BNCT) drugs. The company originated inside Stella Chemifa, the only domestic holder of high-purity boron-10 isotope enrichment technology, and has built its franchise on Steboronine® (borofalan (10B), development code SPM-011) — the world's first BNCT boron pharmaceutical to receive marketing approval (Japan, March 2020) and national health insurance reimbursement (effective May 2020) for unresectable locally advanced or locally recurrent head and neck cancer. The drug pairs an enriched boron-10 compound with external neutron irradiation to selectively destroy cancer cells while sparing surrounding tissue, typically in a single ~40-minute session. The company is actively pursuing indication expansion (recent MAA submissions in March 2026 for angiosarcoma and recurrent high-grade meningioma) and assessing thoracic solid tumors, supported by Phase II data showing median PFS of 14.4 vs 1.4 months in recurrent meningioma and 50% ORR in angiosarcoma.

The business model is a single-asset specialty pharma selling a high-value, reimbursement-covered boron drug directly to BNCT-capable medical institutions, with revenue tightly coupled to the installed base of accelerator-based neutron irradiation systems. Go-to-market is sales-led and education-driven: Stella Pharma co-hosts symposia at major Japanese oncology and head-and-neck surgical societies with Sumitomo Heavy Industries (manufacturer of the NeuCure™ BNCT treatment system), runs physician webinars (120+ participants), and supports patient education. Distribution is direct to a small number of treatment centers in Japan (Osaka Medical and Pharmaceutical University Kansai BNCT Medical Center, Minami Tohoku BNCT Research Center, National Cancer Center) and is being extended internationally through the TAE Life Sciences partnership for the USA/Europe and the Pengbo (Hainan) BNCT Hospital in China (opened February 2026, first overseas BNCT site using Japanese-approved pharmaceutical and equipment). The company remains in early commercialization with revenue not publicly disclosed, headcount of 11–50, and faces a material supply-chain disruption following the September 2025 bankruptcy filing of its contract manufacturer.

STELLA PHARMA firmographics

Firmographics
Name
STELLA PHARMA
Legal name
ステラファーマ株式会社 (STELLA PHARMA CORPORATION)
Website
https://stella-pharma.co.jp
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
STELLA PHARMA (TSE Growth: 4888) is a Japan-based specialty pharmaceutical company developing Steboronine®, the world's first approved Boron Neutron Capture Therapy (BNCT) boron drug, sold to BNCT treatment centers and hospitals for head and neck cancer and pipeline oncology indications in Japan, China, the US, and Europe.
Ownership category
akta.pro rank

STELLA PHARMA industry classification

Industry
Product category
Radiation Therapy Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAE
Radiopharmacy Compounding & Dispensing (Hospital/Commercial)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAKAFAC
Radiation Oncology

Keywords

  • BNCT pharmaceuticals
  • Radiation oncology drugs
  • Boron drug development
  • Neutron capture therapy
  • Cancer therapy products

Where STELLA PHARMA is headquartered

Location

Headquarters

HQ city
Osaka
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

STELLA PHARMA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D

Revenue model

  1. Pharmaceutical Sales - Steboronine®: Sale of BNCT boron pharmaceutical drugs (Steboronine®) for treatment of unresectable locally advanced or locally recurrent head and neck cancer. The drug is used in combination with neutron irradiation systems at BNCT treatment facilities.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

STELLA PHARMA product offering

Product offering

Core offering

STELLA PHARMA develops and commercializes pharmaceutical drugs for Boron Neutron Capture Therapy (BNCT), a radiation therapy that combines a boron-containing drug with neutron irradiation to selectively destroy cancer cells. Its core product, Steboronine® (borofalan (10B), SPM-011), is the world's first approved BNCT boron pharmaceutical, approved in Japan in March 2020 for unresectable locally advanced or locally recurrent head and neck cancer. The company supplies the drug to medical institutions equipped with accelerator-based neutron irradiation systems (such as Sumitomo Heavy Industries' NeuCure™), enabling single-session targeted cancer treatment.

Product overview

STELLA PHARMA is a pharmaceutical company specializing in BNCT (Boron Neutron Capture Therapy) drugs. The company's core product is Steboronine® (development code SPM-011), the world's first approved BNCT pharmaceutical containing enriched boron-10. This drug is used in combination with accelerator-based neutron irradiation systems (such as Sumitomo Heavy Industries' NeuCure™) to selectively destroy cancer cells. BNCT represents a new category of radiation therapy where a single treatment session can complete treatment, targeting cancer cells while preserving surrounding healthy tissue. The company is pursuing indication expansions for recurrent meningioma, angiosarcoma, recurrent high-grade meningioma, and solid tumors.

Differentiator

Problem solved

Functional benefit

Brands

  • Steboronine (ステボロニン): BNCT (Boron Neutron Capture Therapy) boron pharmaceutical product; the world's first approved BNCT drug. Approved in Japan in March 2020 for unresectable locally advanced or locally recurrent head and neck cancer.

Products and services

  • Steboronine® (ステボロニン®) / Borofalan (10B) / SPM-011 World's first approved BNCT (Boron Neutron Capture Therapy) pharmaceutical drug containing enriched boron-10 (borofalan), used in combination with neutron irradiation for targeted cancer treatment. Approved for unresectable locally advanced or locally recurrent head and neck cancer. Sold to BNCT-equipped medical institutions.
  • BNCT (Boron Neutron Capture Therapy) Treatment System Supply Integrated BNCT treatment offering that pairs STELLA PHARMA's Steboronine® drug with accelerator-based neutron irradiation systems (e.g., Sumitomo Heavy Industries' NeuCure™). When boron-10 absorbs thermal neutrons, it produces alpha particles and lithium nuclei that selectively destroy cancer cells while minimizing damage to surrounding healthy tissue. Treatment is typically completed in a single session of approximately 40 minutes.

Quantifiable outcome

  • Head and neck cancer treatment outcomes: Tumor shrinkage confirmed in all reported BNCT treatment cases at insurance-covered facilities
  • +2 more outcomes

Companies that use STELLA PHARMA

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles2 records

STELLA PHARMA technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

STELLA PHARMA partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, flagship and minor.

  • Pengbo (Hainan) BNCT Hospital / 鵬博(海南)BNCTセンターcoreGTM or Marketing Partner · 7 February 2026First overseas BNCT facility to use Japanese-approved pharmaceuticals and medical equipment. Located in Hainan Boao Lecheng International Medical Tourism Pilot Zone, China. Stella Pharma supplies BNCT drugs; facility officially opened February 2026 with Sumitomo Heavy Industries BNCT system installed.
  • Sumitomo Heavy Industries Co., Ltd. (住友重機械工業株式会社)coreStrategic or Co-development Partner · 13 November 2024Joint development and commercialization partnership for BNCT treatment systems in Japan and globally. Sumitomo Heavy Industries develops and manufactures accelerator-based neutron irradiation systems (NeuCure™) while Stella Pharma supplies the boron pharmaceutical (Steboronine®). The companies jointly conduct clinical trials and promotional activities including academic conference seminars.
  • TAE Life Sciences US, LLC (TLS社)flagshipStrategic or Co-development Partner · 13 November 2024Strategic partnership for development and commercialization of BPA (boronophenylalanine) for BNCT cancer therapy in USA and Europe. Signed at TLS headquarters in California, the partnership aims to expand BNCT market in Western regions. CEO Rob from TLS and President Ehara from Stella Pharma participated in signing ceremony.
  • Stella Chemifa Co., Ltd. (ステラケミファ株式会社)coreTechnology or IntegrationParent company and exclusive domestic holder of boron isotope enrichment technology in Japan. Provides 10B isotope enrichment capabilities (99%+ concentration) essential for BNCT pharmaceutical production.
  • Osaka Metropolitan University (大阪府立大学)minorStrategic or Co-development PartnerAcademic partnership for BNCT research. Professor Kirihata from Osaka Metropolitan University BNCT Research Center collaborated on research and development of boron pharmaceuticals.
  • Kyoto University (京都大学)minorStrategic or Co-development PartnerAcademic partnership for BNCT research and development. Kyoto University Research Reactor was used for early BNCT clinical research. Company leveraged Kyoto University research as foundation for drug development.
  • Osaka Medical and Pharmaceutical University Kansai BNCT Medical Center (大阪医科薬科大学関西BNCT共同医療センター)coreStrategic or Co-development PartnerPrimary BNCT treatment facility in Japan; key site for clinical trials and treatment delivery. Professor Aihara from the center serves as key opinion leader and frequently presents BNCT clinical data at conferences.
  • National Cancer Center Central Hospital (国立がん研究センター中央病院)coreStrategic or Co-development PartnerLeading cancer treatment hospital conducting BNCT treatments and clinical trials. Dr. Igaki from the hospital participates in BNCT education and awareness activities, including TV media appearances.
  • Japan Agency for Medical Research and Development (AMED) / 国立研究開発法人日本医療研究開発機構minorStrategic or Co-development PartnerGovernment research funding agency providing support for BNCT drug development. Company received A-STEP and ACT-M program support for clinical development and novel formulation research.
  • Sagamihara General Hospital (湘南鎌倉総合病院)minorStrategic or Co-development PartnerResearch collaboration on enhanced proton beam therapy using boron compounds. Company provides reagents for research study on cell killing effect enhancement published in Scientific Reports.
  • CICS Co., Ltd. (株式会社CICS)minorStrategic or Co-development PartnerJoint clinical trial partnership for BNCT treatment of angiosarcoma. CICS provides neutron irradiation system (CICS-1) while Stella Pharma supplies boron drug (SPM-011) for Phase II clinical trial.
  • China Biotech Services Holdings Limited / 中国生物科技服務控股有限公司 (Hong Kong Stock Exchange: 8037)flagshipGTM or Marketing PartnerChinese partner company for Hainan Island BNCT center operations. Publicly listed company managing Pengbo BNCT hospital in Boao Lecheng zone. Awarded recognition for BNCT technology at 6th China International Consumer Goods Expo.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

STELLA PHARMA competitors and assessment

Company assessment

Broad incumbents

  • Sumitomo Heavy Industries: Manufacturer of the NeuCure™ accelerator-based BNCT system used in conjunction with Steboronine®; a strategic co-development partner but also an adjacent competitor/ecosystem gatekeeper in the BNCT value chain.
  • Novartis (Pluvicto / Radioligand Therapy): Leader in therapeutic radiopharmaceuticals (e.g., Pluvicto for prostate cancer, Lutathera) — overlaps with Stella Pharma's targeted radionuclide therapy positioning in oncology.
  • Bayer (Xofigo / Radiopharmaceuticals): Major radiopharmaceutical player with Xofigo (Ra-223) for bone metastases — comparable therapeutic radiopharmaceutical business with established oncology distribution.

Direct peers

  • TAE Life Sciences: US-based BNCT company developing accelerator systems and BPA-based boron drugs; signed a strategic partnership with Stella Pharma in Nov 2024 to commercialize BPA in USA/Europe — directly comparable BNCT drug-and-device player.
  • Lantheus Holdings: US-listed radiopharmaceutical company specializing in diagnostic and therapeutic radioisotopes — comparable business model in radiopharma drug development and commercialization.
  • Telix Pharmaceuticals: Radiopharmaceutical company developing diagnostic and therapeutic agents (e.g., Illuccix, TLX591) — directly comparable in targeted radioisotope drug development pipeline.
  • ITM Isotope Technologies Munich: Manufacturer of medical radioisotopes (including Lu-177) and developer of targeted radiopharmaceuticals — comparable in isotope-based oncology therapeutics.

Others

Regional players

  • Ion Beam Applications (IBA): Belgian proton therapy equipment manufacturer; adjacent player in particle-beam radiation therapy ecosystem relevant to BNCT's positioning vs proton therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

STELLA PHARMA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

STELLA PHARMA leadership team

Management profile

Number of profiles

Profiles2 records

STELLA PHARMA funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

STELLA PHARMA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STELLA PHARMA

What does STELLA PHARMA do?

STELLA PHARMA develops and commercializes pharmaceutical drugs for Boron Neutron Capture Therapy (BNCT), a radiation therapy that combines a boron-containing drug with neutron irradiation to selectively destroy cancer cells. Its core product, Steboronine® (borofalan (10B), SPM-011), is the world's first approved BNCT boron pharmaceutical, approved in Japan in March 2020 for unresectable locally advanced or locally recurrent head and neck cancer. The company supplies the drug to medical institutions equipped with accelerator-based neutron irradiation systems (such as Sumitomo Heavy Industries' NeuCure™), enabling single-session targeted cancer treatment.

Is STELLA PHARMA a public or private company?

STELLA PHARMA is a public company. It is classified as public and is currently operating.

When was STELLA PHARMA founded?

STELLA PHARMA was founded in 2007. It employs 1 to 10 people.

Where is STELLA PHARMA based?

STELLA PHARMA is headquartered in Osaka, Japan, in the Asia region.

How does STELLA PHARMA make money?

One revenue line is on record: pharmaceutical Sales - Steboronine®.

Who are STELLA PHARMA's main competitors?

Broad incumbents on record are Sumitomo Heavy Industries, Novartis (Pluvicto / Radioligand Therapy) and Bayer (Xofigo / Radiopharmaceuticals). Direct peers are TAE Life Sciences, Lantheus Holdings, Telix Pharmaceuticals and ITM Isotope Technologies Munich. Others are Cardinal Health (Radiopharmaceutical Distribution) and PETNET Solutions (Siemens Healthineers). Ion Beam Applications (IBA) is listed as a regional player.

Does STELLA PHARMA have an API?

No public API is recorded for STELLA PHARMA.

What industry is STELLA PHARMA in?

STELLA PHARMA's product category is Radiation Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAE, Radiopharmacy Compounding & Dispensing (Hospital/Commercial). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals